Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Effects of Rifampicin on HRS-1167 in Healthy Subjects
NCT06198556Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of M9466 in solid tumor, sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to the last measurable concentration and 1 more. Started Jan 2024; status: completed.
02
Drugs
M9466
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06198556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06198556.